Fort Myers Newswire

Fort Myers Newswire

Comprehensive Real-Time News Feed for Fort Myers, FL.

Results 1 - 20 of 25 for "u:americanbankingnews.com" in Fort Myers, FL

  1. NeoGenomics Inc. (NEO) Rating Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Wednesday | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  2. NeoGenomics Inc. (NEO) Lowered to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    Sunday Sep 25 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  3. NeoGenomics Inc. (NEO) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Aug 29, 2016 | AmericanBankingNews.com

    The brokerage presently has a $9.25 price objective on the stock. Zacks Investment Research's price objective would indicate a potential upside of 14.48% from the company's current price.

    Comment?

  4. Analysts' Recent Ratings Changes for NeoGenomicsRead the original story w/Photo

    Aug 4, 2016 | AmericanBankingNews.com

    They now have a $9.25 price target on the stock. According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.

    Comment?

  5. NeoGenomics Inc. (NEO) Rating Increased to Buy at Zacks Investment ResearchRead the original story w/Photo

    Aug 4, 2016 | AmericanBankingNews.com

    The brokerage currently has a $9.25 price target on the stock. Zacks Investment Research's price objective indicates a potential upside of 11.18% from the company's current price.

    Comment?

  6. Investment Analysts' Downgrades for July, 28th (ASH, DNKN, DTY, ...Read the original story w/Photo

    Jul 28, 2016 | AmericanBankingNews.com

    The firm currently has $119.00 target price on the stock, down from their previous target price of $122.00. was downgraded by analysts at Credit Agricole SA from an outperform rating to an underperform rating.

    Comment?

  7. NeoGenomics Inc. (NEO) Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Jul 27, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  8. Recent Research Analysts' Ratings Changes for NeoGenomicsRead the original story w/Photo

    Jul 15, 2016 | AmericanBankingNews.com

    They now have a $10.00 price target on the stock. 7/7/2016 - NeoGenomics was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating.

    Comment?

  9. NeoGenomics Inc. (NEO) Upgraded by Zacks Investment Research to BuyRead the original story w/Photo

    Jul 9, 2016 | AmericanBankingNews.com

    The firm presently has a $9.25 price objective on the stock. Zacks Investment Research's target price would suggest a potential upside of 1.09% from the company's previous close.

    Comment?

  10. NeoGenomics Inc. (NEO) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Jul 7, 2016 | AmericanBankingNews.com

    The brokerage currently has a $9.25 target price on the stock. Zacks Investment Research's price objective indicates a potential upside of 13.22% from the stock's current price.

    Comment?

  11. NeoGenomics Inc. (NEO) Rating Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Jul 3, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  12. Zacks Investment Research Lowers NeoGenomics, Inc. (NEO) to HoldRead the original story w/Photo

    Jun 29, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  13. NeoGenomics, Inc. (NEO) Upgraded to "Strong-Buy" by Zacks Investment ResearchRead the original story w/Photo

    May 25, 2016 | AmericanBankingNews.com

    They currently have $9.75 price objective on the stock. According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.

    Comment?

  14. NeoGenomics, Inc. (NEO) Rating Increased to Strong-Buy at Zacks Investment ResearchRead the original story w/Photo

    May 20, 2016 | AmericanBankingNews.com

    The brokerage presently has a $9.75 price target on the stock. Zacks Investment Research 's price objective would suggest a potential upside of 13.37% from the company's current price.

    Comment?

  15. NeoGenomics, Inc. (NEO) Upgraded to "Strong-Buy" at Zacks Investment ResearchRead the original story w/Photo

    May 20, 2016 | AmericanBankingNews.com

    The firm presently has a $9.75 price target on the stock. Zacks Investment Research 's target price would indicate a potential upside of 13.37% from the stock's current price.

    Comment?

  16. NeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to Strong-BuyRead the original story w/Photo

    May 19, 2016 | AmericanBankingNews.com

    The brokerage currently has a $9.75 target price on the stock. Zacks Investment Research 's price target suggests a potential upside of 15.11% from the stock's previous close.

    Comment?

  17. NeoGenomics, Inc. (NEO) Downgraded by Zacks Investment ResearchRead the original story w/Photo

    Mar 22, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  18. NeoGenomics (NEO) - Analysts' Recent Ratings ChangesRead the original story w/Photo

    Mar 22, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  19. NeoGenomics, Inc. (NEO) Upgraded to "Buy" at Zacks Investment ResearchRead the original story w/Photo

    Mar 22, 2016 | AmericanBankingNews.com

    The brokerage currently has $7.50 price target on the stock. According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.

    Comment?

  20. Weekly Investment Analysts' Ratings Updates for NeoGenomicsRead the original story w/Photo

    Mar 21, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

Fort Myers Job Listings
View or post Fort Myers job listings on Topix.
Fort Myers Real Estate
News, listings, and foreclosures in Fort Myers from Topix.
Fort Myers Mortgages
Find mortgage rates in Fort Myers on Topix.